Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 48 for:    alogliptin
Previous Study | Return to List | Next Study

Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00957268
First received: August 6, 2009
Last updated: December 20, 2013
Last verified: December 2013

August 6, 2009
December 20, 2013
November 2009
November 2013   (final data collection date for primary outcome measure)
  • Plasma pharmacokinetic primary endpoint for alogliptin: maximum observed plasma concentration (Cmax) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Plasma pharmacokinetic primary endpoint for alogliptin: time to reach Cmax (Tmax) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Plasma pharmacokinetic primary endpoint for alogliptin: area under the plasma concentration-time curve from time 0 to infinity (AUC[0-inf]) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00957268 on ClinicalTrials.gov Archive Site
  • Pharmacodynamic secondary endpoint for dipeptidyl peptidase-4 (DPP-4) inhibition: area under the plasma effect-time curve from time 0 to time of the last quantifiable effect (AUEC[0-24]) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Pharmacodynamic secondary endpoint for DPP-4 inhibition: maximum observed effect (Emax) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Pharmacodynamic secondary endpoint for DPP-4 inhibition: time to reach maximum observed effect (Tmax) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Pharmacodynamic secondary endpoint for DPP-4 inhibition: observed effect at 24 hours after dosing (E24) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Pharmacodynamic secondary endpoint for glucagon-like peptide-1 (GLP-1): area under the plasma effect-time curve from time 0 to time of the last quantifiable effect (AUEC[0-24]) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Pharmacodynamic secondary endpoint for GLP-1 : maximum observed effect (Emax) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Pharmacodynamic secondary endpoint for GLP-1 : time to reach maximum observed effect (Tmax) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Pharmacodynamic secondary endpoint for GLP-1 : observed effect at 24 hours after dosing (E24) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults With Type 2 (Non-Insulin Dependent) Diabetes Mellitus

The purpose of this study is to determine the pharmacokinetic and safety profile of Alogliptin in children, adolescents and adults with Type 2 Diabetes Mellitus.

Alogliptin is a selective, orally available inhibitor of dipeptidyl peptidase-4 being developed by Takeda Global Research & Development Center, Inc. as a treatment for type 2 diabetes mellitus. Inhibition of dipeptidyl peptidase-4 (DPP-4) prolongs the action of 2 important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are responsible for increasing insulin synthesis, regulating β-cell proliferation, inhibiting gastric emptying, and inhibiting glucagon secretion.

To date, alogliptin has not been studied in participants less than 18 years of age. As with adults, there is growing evidence of an increase in the prevalence of type 2 diabetes mellitus in children and adolescents.

This study is designed to determine the pharmacokinetic, pharmacodynamic, and safety profile of alogliptin in children and adolescents with type 2 diabetes mellitus. These profiles will be compared with those of similarly matched adult subjects with type 2 diabetes mellitus. Pharmacokinetic, pharmacodynamic and safety endpoints will be analyzed.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Diabetes Mellitus, Type 2
  • Drug: Alogliptin
    Alogliptin 12.5 mg, tablets, orally, 1 day only.
    Other Name: SYR-322
  • Drug: Alogliptin
    Alogliptin 25 mg, tablets, orally, 1 day only.
    Other Name: SYR-322
  • Drug: Alogliptin
    Alogliptin 12.5 mg, tablets, orally, 1 day only
    Other Name: SYR-322
  • Drug: Alogliptin
    Alogliptin 25 mg, tablets, orally, 1 day only
    Other Name: SYR-322
  • Experimental: Alogliptin 12.5 mg (Pediatrics)
    (age 10 to less than 14 years)
    Intervention: Drug: Alogliptin
  • Experimental: Alogliptin 25 mg (Pediatrics)
    (age 10 to less than 14 years)
    Intervention: Drug: Alogliptin
  • Experimental: Alogliptin 12.5 mg (Adolescents)
    (age 14 to less than 18 years)
    Intervention: Drug: Alogliptin
  • Experimental: Alogliptin 25 mg (Adolescents)
    (age 14 to less than 18 years)
    Intervention: Drug: Alogliptin
  • Experimental: Alogliptin 25 mg (Adults)
    (age 18 to 65 years)
    Intervention: Drug: Alogliptin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
November 2013
November 2013   (final data collection date for primary outcome measure)

Inclusion criteria for children and adolescent participants (between 10 and 17 years of age):

  • Is capable of understanding an informed consent form (ICF) or assenting to participate. The parent or legal guardian of the participant must be able to understand and sign a written ICF prior to the initiation of any study procedures.
  • Weighs at least 36 kg (79 pounds) and has a Screening Body Mass Index of at least 18 kg/m2.
  • Participants must have a diagnosis of Type 2 Diabetes Mellitus (non-insulin dependent) based on diagnostic criteria of the American Diabetes Association. Criteria include:

    • fasting plasma glucose level of greater than or equal to 126 mg/dL where fasting is defined as no caloric intake for at least 8 hours, or
    • 2-hour plasma glucose level of greater than or equal to 200 mg/dL during an oral glucose tolerance test, or
    • random plasma glucose level of greater than or equal to 200 mg/dL, or
    • glycated Hemoglobin greater than or equal 6.5%.
  • Diagnosis can be historical (documented), or subjects can be diagnosed for this study.
  • Subjects must have a fasting serum C-peptide concentration greater than or equal to 0.8 ng/mL (greater than or equal to 0.26 nmol/L) at Screening Visit only.
  • Subjects may be taking concomitant metformin if the dose has been stable for at least 30 days prior to Day 1.

Inclusion criteria for gender and race matched adult participants (between 18 and 65 years of age):

  • Weighs at least 50 kg (110 pounds) and has a Screening Body Mass Index between 23 kg/m2 and 45 kg/m2 (except for Asian or Asian-descendant subjects for whom the range is between 20 kg/m2 and 35 kg/m2), inclusive for gender and race matched Type 2 Diabetes Mellitus adult subjects only.
  • Subjects must have a diagnosis of Type 2 Diabetes Mellitus (non-insulin dependent) based on diagnostic criteria of the American Diabetes Association. Criteria include:

    • Fasting plasma glucose level of greater than or equal to 126 mg/dL where fasting is defined as no caloric intake for at least 8 hours, or
    • 2-hour plasma glucose level of greater than or equal to 200 mg/dL during an oral glucose tolerance test, or
    • random plasma glucose level of greater than or equal to 200 mg/dL, or
    • glycated Hemoglobin greater than or equal 6.5%.
  • Diagnosis can be historical (documented) or subjects can be diagnosed for this study.
  • May be taking concomitant metformin if the dose has been stable for at least 30 days prior to Day 1.
  • May be taking statin or antihypertensive drugs if the dose has been stable for at least 30 days prior to Day 1.

Inclusion criteria for all participants:

  • Female participants of childbearing potential and male subjects who are sexually active agree to routinely use adequate contraception from Screening until 30 days after receiving the dose of study drug.
  • Must have a negative urine test result for selected substances of abuse (including alcohol and cotinine) at Screening and Check-in (Day -1).
  • Has clinical chemistry, hematology, and complete urinalysis (fasted for at least 8 hours) results within the reference range for the testing laboratory (except results associated with Type 2 Diabetes Mellitus) unless the out-of-range results are deemed not clinically meaningful by the investigator or sponsor.
  • Has a negative test result for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV), and no known history of human immunodeficiency virus (HIV).

Exclusion Criteria:

  • Is currently participating in another investigational study or has taken an investigational drug within 30 days prior to Day 1.
  • Received alogliptin previously.
  • Received or donated blood or blood products within 30 days prior to Screening or plans to donate blood during the study.
  • Has a known hypersensitivity to alogliptin or related compounds.
  • Has a history of drug abuse or a history of alcohol abuse within 1 year prior to study Day 1.
  • Has had an acute, clinically significant illness (excluding Type 2 Diabetes Mellitus) within 30 days prior to study Day 1.
  • Has any other condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.
  • Has a history or clinical manifestations of significant metabolic (excluding Type 2 Diabetes Mellitus), hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, immunologic, musculoskeletal or psychiatric disorder.
  • Has a hemoglobin value less than 12 g/dL.
  • Has a systolic blood pressure greater than 140 mm Hg or has a diastolic blood pressure greater than 90 mm Hg at Screening or Check-in (Day -1).
  • Adult subject has an alanine aminotransferase or aspartate aminotransferase level greater than 2 times the upper limit of normal active liver disease, or jaundice at the Screening Visit or on Check-in (Day -1).
  • Pediatric subject has an alanine aminotransferase or aspartate aminotransferase level greater than 1.5 times the upper limit of normal at the Screening Visit or on Check-in (Day -1).
  • Has a serum creatinine level greater than 1.5 mg/dL.
  • Has a creatinine clearance less than 50 mL/min (normalized to body surface area of 1.73 m2).
  • Has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy) or thoracic or nonperipheral vascular surgery within 6 months prior to Day 1.
  • Has a history or presence of a clinically significant abnormal 12-lead Electrocardiogram result as determined by the investigator or Takeda Global Research and Development at Screening or Check-in (Day -1).
  • Has a history of cancer, other than basal cell carcinoma or Stage I squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.
  • If female, subject is pregnant or lactating or intending to become pregnant before, during, or within 30 days after receiving study drug.
  • If male, subject intends to impregnate others during the study or for 30 days after receiving study drug.
  • Has consumed or is unable to abstain from consumption of products containing alcohol, caffeine, or xanthine, and food or beverages containing grapefruit juice or Seville-type oranges within 72 hours prior to study Day 1 and for the duration of the study.
  • Used any tobacco (ie, nicotine) products within 6 weeks prior to study Day 1, and is unwilling to abstain from these products for the duration of the study.
  • Has used any nutraceutical preparations within 28 days prior to study Day 1.
  • Is currently taking ketoconazole, fluconazole, gemfibrozil, rifampin or carbamazepine or taken within 28 days prior to Check-in (Day -1).
  • Has poor peripheral venous access.
  • Has a medical history of clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes or secondary forms of diabetes including maturity-onset diabetes of the young (MODY).
Both
10 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00957268
SYR-322_104, 2009-011221-13, U1111-1111-7810
No
Takeda
Takeda
Not Provided
Study Director: VP Clinical Science Takeda
Takeda
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP